ArticleCureus2026
Pre-operative Axillary Staging in Breast Cancer: Implications and Outcome.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Axillary ultrasonography (AUS) and US-guided needle core biopsy (NCB) are recommended for evaluating axillary nodal status in new breast cancer cases. Presence of axillary nodal metastasis significantly impacts five-year survival rates. This study evaluated the diagnostic accuracy of preoperative AUS and US‑guided NCB in patients with invasive breast cancer at Leighton Hospital, benchmarked against national NHS standards. The primary objective was to assess the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of AUS and NCB in detecting nodal metastasis. Methodology This retrospective study was conducted at the Breast Unit of Leighton Hospital, part of the Mid Cheshire Hospital Trust. The study population included all patients diagnosed and treated for breast cancer from January 1, 2022, to December 31, 2022. Patients presenting with locally advanced, metastatic, or recurrent breast cancer were excluded from the study. Ultrasound evaluations were performed using a high-frequency linear-array transducer (7.5-17 MHz). Patients with in situ disease were not subject to axillary assessment/surgery. Lymph nodes with cortical thickness of 3 mm or more, irregular margins, and effacement of the fatty hilum were considered suspicious and were graded A3 and above. All these patients were subjected to US‑guided NCB. Patients graded A1/A2 and those with biopsy-proven benign nodes had sentinel node biopsy. Patients with positive biopsy for metastatic disease were subjected to axillary lymph node dissection (ALND). Results Axillary assessment for patients graded A3 and above (Group B) met or exceeded NHS standards for sensitivity (0.93), specificity (0.92), and PPV (0.92). NPV (0.92) was slightly below NHS standard. The lower performance metrics in Group B (A1-5) fell short of NHS guidelines in all four metrics, highlighting the need for potential improvements in the diagnostic process or the use of additional diagnostic tools to enhance accuracy. Conclusion Axillary assessment in A3 patients met or exceeded NHS standards, with sensitivity, specificity, and PPV at 0.92, though NPV was slightly lower. A1/A2 patients underperformed across all measures. The findings support AUS as a reliable tool for breast cancer staging and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.